A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07431866
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
24 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Rosuvastatin — DRUG
    Oral administration
  • Furosemide — DRUG
    Oral administration
  • MK-2828 — DRUG
    Oral administration

Study Details

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Key Dates

Start date
Mar 18, 2026
Status verified
Jun 2026
Primary completion
Jun 13, 2026
Completion
Jun 13, 2026

Study Design

Enrollment
39 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Rosuvastatin + MK-2828
    Participants receive rosuvastatin and MK-2828 orally.
  • Experimental: Furosemide + MK-2828
    Participants receive furosemide and MK-2828 orally.

Primary Outcome Measure

Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin [ Time Frame: At designated time points (up to approximately 2 weeks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Inc ( Site 0001)Daytona BeachFlorida32117-

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit Inc· Daytona Beach, FL

Related Studies